Trials / Completed
CompletedNCT02298387
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- OncoMed Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Detailed description
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OMP-305B83 | intravenous (in the vein) infusions |
Timeline
- Start date
- 2014-12-22
- Primary completion
- 2017-05-23
- Completion
- 2017-09-08
- First posted
- 2014-11-24
- Last updated
- 2020-08-11
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02298387. Inclusion in this directory is not an endorsement.